Royalty Report: Drugs, cardiac, Disease – Collection: 263954

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Enzymes

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 263954

License Grant
The German Licensor grants an exclusive right and license in the Territory, under Licensors Technology, for all Pharmaceutical Uses, with the right to grant sublicenses, to research, develop, modify and improve Compound and Product;  apply for and obtain Regulatory Approvals; and use, import/export, market, offer to sell and sell, Product and Compound.
License Property
The Compound means the endothelin receptor antagonist compound identified as BSF 208075 (ambrisentan) and the chemical name, (+)-(S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3- diphenyl propionic acid, its racemates, isomers, Prodrugs, active metabolites and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation.
Field of Use
The license is for any pharmaceutical use.  The clinical study of the compound is for pulmonary arterial hypertension, Chronic Renal Failure and Chronic Heart Failure.

IPSCIO Record ID: 328142

License Grant
The University grants
–  an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and,
–  an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and
–  an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed Products in the Fields of Use and to practice any Licensed Process in the Fields of Use.
License Property
Licensor has rights to technology relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol.

Bucindolol means the beta-adrenergic–receptor antagonist having the chemical formula 2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in connection with its prescription.

Bucindolol Invention shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development of Bucindolol.

Patents are titled
Expression Profiling in the Intact Human Heart,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Alpha-le Adrenergic
     Receptor,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Beta-1 Adrenergic
     Receptor, and,
Methods for Treatment with Bucindolol Based on Genetic Targeting.

Field of Use
Fields of use is all fields.

Licensee is focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases.

IPSCIO Record ID: 263955

License Grant
Licensor grants an exclusive right and license in the Licensee Territory, under the Licensor Technology, for all uses in the Field, with the right to grant sublicenses, to research, develop, modify and improve Compound and Product;  apply for and obtain Regulatory Approvals; and use, import/export, market, offer to sell and sell, Product and Compound; and make, or have made, the Compound and Product for use in the Field.
License Property
The Compound means the compound identified as LU 135252 (Darusentan) and its racemates, isomers, Prodrugs, active metabolites and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation.
Field of Use
The Field means all human and non-human diagnostic, prophylactic and therapeutic uses of the Compound and/or Product in any formulation or dosage form for any and all indications except therapeutic uses and indications in the Cancer Field.

Cancer Field means the prophylactic or therapeutic administration to humans or non-human animals as an agent, either alone or in combination with other agents, for the prevention, treatment or palliation of cancer including neoadjuvant, adjuvant or supportive care and/or as part of combination with radiotherapy, surgery, chemo-, biologic- or other therapy associated with cancer, including, but not limited to, pain and bone/skeletal complications or indications from bone metastasis.

IPSCIO Record ID: 286027

License Grant
Licensor hereby grants to Koran Licensee a sole and exclusive right and license in the Territory to use and sell any of the Products for the indications as specified herein.
License Property
Product means (a) TBC-11251, the lead candidate for Licensors Endothelin Receptor Antagonist (TBC-11251 is more particularly described hereto), and/or (b) TBC-1269, the lead candidate for Licensors Selectin Antagonist (TBC-1269 is more particularly described hereto).

TBC11251 is a sulfonamide based antagonist of endothelin binding to its receptors. The compound exhibits selectivity for binding to the A subtype of the endothelin receptors relative to the B subtype. The chemical structure of TBC11251 is 4-chloro-3-methyl-5-(2-(2-(6-methylbenzo[d][1.3]dioxol-5-yl)acetyl)-3-thienylsulfonamido)isoxazole (it is also referred to by N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5- (methylenedioxy)phenylacetyl]thiophene-3-sulfphonamide). The compound is also referred to as various salt forms which include, but are not limited to, the sodium phosphate salt (TBC11251Z) and the sodium salt (TBC11251Na).

Application 1 PCT/US94/05755 'Sulfonamides and derivatives thereof that modulate the activity of endothelin' filed April 4, 1994.

Application 2 PCT/US96/04759 'Thienyl-, furyl, pyrrolyl-, and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin' filed April 4, 1996.

TBC1269 is a mannosylated biphenyl based selectin antagonist which is capable of blocking the binding of E-,P-, and L- selectin to their respective ligands. The compound is also referred to as various sale forms which include, but are not limited to, the sodium salt (TBC1269Na).

Patents covering TBC1269 in the Territories
Application PCT/US96/11032 entitled 'Binding of E-selecting, P-selectin or L-selectin to Sialyl-Lewis or Sialyl-Lewis' filed June 26, 1996.
Application 08/655 entitled 'High yield stereospecific mannosylation' filed May 20, 1996.

Endothelin Receptor Antagonist means a molecular compound under development by Licensor which inhibits the binding of endothelin to a distinct cell surface receptor.

Novastan(R) means a non-protein, synthetic small molecule thrombin inhibitor developed by Licensor that directly and selectively binds to and inactivates thrombin in the blood plasma.

Selectin Antagonist means a molecular compound under development by Licensor which inhibits the selectin-mediated adhesion of inflamed endothelium to the surface of white blood cells.

Endothelin receptors are G protein-coupled receptors whose activation result in elevation of intracellular-free calcium,[2] which constricts the smooth muscles of the blood vessels, raising blood pressure, or relaxes the smooth muscles of the blood vessels, lowering blood pressure, among other functions.

Field of Use
This agreement pertains to the drug industry relating to indications of congestive heart failure , chronic obstructive pulmonary disease, primary pulmonary hypertension, asthma and psoriasis.

IPSCIO Record ID: 26543

License Grant
Licensor hereby grants to Licensee an Exclusive License in the Territory, under Licensort Technology, for all Pharmaceutical Uses, with the right to grant sublicenses to (i) research, develop, make or have made, Compound A, Compound B and Product(s); (ii) apply for and obtain Regulatory Approvals, all as may be required to manufacture and commercialize Product(s); and (iii) register, use, import/export, market, offer to sell and sell, Product(s) and Compound A and Compound B.
License Property
COMPOUND A means the compound known as ABT-773, its enantiomers, racemates, isomers and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation, and including any Prodrugs and active metabolites, whether made before or after the Effective Date.

COMPOUND B means the compound known as ABT-210, its enantiomers, racemates, isomers and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation, and including any Prodrugs and active metabolites, whether made before or after the Effective Date.  Commercialize cethromycin, a novel ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections. Ketolides, a new class of antibiotic to treat respiratory tract infections, have demonstrated strong activity against bacteria that are resistant to many currently marketed antibiotics. Following the offerings, we intend to conduct two pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate community acquired pneumonia.

Field of Use
The rights granted apply to Pharmaceutical Uses.

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.

IPSCIO Record ID: 294283

License Grant
Licensor grants to the Licensee of Japan an exclusive license in the Territory to use Licensor Know-how and the Licensed Compound to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Product(s).

Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.

License Property
Licensor has Know-How and the Patent Rights relating to the antidyslipidemic compound known as BT16.

BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.

BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.

Licensed Compound shall mean BT16.

The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.

BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.

Field of Use
The phase II compound BT16 is r the treatment of dyslipidemia.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.  Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.

Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.